KR20220032004A - DUX4 프리-mRNA의 스플라이싱을 변화시키는 안티센스 올리고뉴클레오티드 - Google Patents

DUX4 프리-mRNA의 스플라이싱을 변화시키는 안티센스 올리고뉴클레오티드 Download PDF

Info

Publication number
KR20220032004A
KR20220032004A KR1020217040852A KR20217040852A KR20220032004A KR 20220032004 A KR20220032004 A KR 20220032004A KR 1020217040852 A KR1020217040852 A KR 1020217040852A KR 20217040852 A KR20217040852 A KR 20217040852A KR 20220032004 A KR20220032004 A KR 20220032004A
Authority
KR
South Korea
Prior art keywords
dux4
oligonucleotide
pharmaceutically acceptable
acceptable salt
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217040852A
Other languages
English (en)
Korean (ko)
Inventor
마코토 고이즈미
아키후미 나카무라
다카히로 가타기리
히로아키 미츠하시
Original Assignee
다이이찌 산쿄 가부시키가이샤
토카이 유니버시티 에듀케이셔널시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이이찌 산쿄 가부시키가이샤, 토카이 유니버시티 에듀케이셔널시스템 filed Critical 다이이찌 산쿄 가부시키가이샤
Publication of KR20220032004A publication Critical patent/KR20220032004A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217040852A 2019-07-12 2020-07-10 DUX4 프리-mRNA의 스플라이싱을 변화시키는 안티센스 올리고뉴클레오티드 Withdrawn KR20220032004A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2019-129735 2019-07-12
JP2019129735 2019-07-12
PCT/JP2020/026950 WO2021010301A1 (ja) 2019-07-12 2020-07-10 ＤＵＸ４ ｐｒｅ－ｍＲＮＡのスプライシングを変化させるアンチセンスオリゴヌクレオチド

Publications (1)

Publication Number Publication Date
KR20220032004A true KR20220032004A (ko) 2022-03-15

Family

ID=74210830

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217040852A Withdrawn KR20220032004A (ko) 2019-07-12 2020-07-10 DUX4 프리-mRNA의 스플라이싱을 변화시키는 안티센스 올리고뉴클레오티드

Country Status (11)

Country Link
US (1) US20220364086A1 (https=)
EP (1) EP3998108A4 (https=)
JP (1) JP7627495B2 (https=)
KR (1) KR20220032004A (https=)
CN (1) CN114026234A (https=)
AU (1) AU2020313255A1 (https=)
BR (1) BR112021024764A2 (https=)
CA (1) CA3142925A1 (https=)
IL (1) IL288596A (https=)
TW (1) TW202117015A (https=)
WO (1) WO2021010301A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230023612A (ko) 2020-04-02 2023-02-17 마이레큘, 인크. 조작된 올리고뉴클레오티드를 사용한 표적화된 억제

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0787982A (ja) 1993-01-29 1995-04-04 Sankyo Co Ltd 修飾オリゴデオキシリボヌクレオチド
US6096881A (en) 1997-05-30 2000-08-01 Hybridon, Inc. Sulfur transfer reagents for oligonucleotide synthesis
JP4236812B2 (ja) 1997-09-12 2009-03-11 エクシコン エ／エス オリゴヌクレオチド類似体
ES2234563T5 (es) 1999-02-12 2018-01-17 Daiichi Sankyo Company, Limited Nuevos análogos de nucleósidos y oligonucleótidos
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
ES2596977T3 (es) * 2010-09-02 2017-01-13 Université de Mons Agentes útiles en el tratamiento de la distrofia muscular facioescapulohumeral
EP2736539B1 (en) * 2011-07-25 2017-08-23 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of dux4
WO2013120038A2 (en) * 2012-02-10 2013-08-15 Regents Of The University Of Minnesota Morpholino targeting dux4 for treating fshd
WO2014109384A1 (ja) 2013-01-10 2014-07-17 塩野義製薬株式会社 架橋型核酸誘導体の製造方法
US20180237775A1 (en) * 2015-09-21 2018-08-23 Association Institut De Myologie Antisense oligonucleotides and uses thereof
JP6966463B2 (ja) * 2016-02-26 2021-11-17 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 組換えウイルス産物及びｄｕｘ４エクソンスキッピングを誘導するための方法
CN109462995A (zh) 2016-05-04 2019-03-12 波涛生命科学有限公司 生物活性剂的方法和组合物
WO2019060432A2 (en) * 2017-09-19 2019-03-28 Children's National Medical Center GAPMERS AND METHODS OF USING THE SAME FOR THE TREATMENT OF MUSCLE DYSTROPHY
JP2019129735A (ja) 2018-01-30 2019-08-08 株式会社ＧＩＳｕｐｐｌｙ 有害動物の捕獲支援システム

Non-Patent Citations (32)

* Cited by examiner, † Cited by third party
Title
Arahata et al., Muscle Nerve 1995, 2:S56-S66
Banerji et al., Nat Commun 2017, 8:2152
Bosnakovski et al., EMBO J 2008, 27:2766-2779
Bosnakovski et al., Nat Commun 2017, 8:550
Choi et al., Nucleic Acids Res 2016, 44:5161-5173
De laco et al., Nat Genet 2017, 49:941-945
Deenen et al., Neurology 2014, 83:1056-1059
Feng et al., eLife 2015, 4:e04996
Gabriels et al., Gene 1999, 236:25-32
Geng et al., Dev Cell 2012, 22:38-51
Hendrickson et al., Nat Genet 2017, 49:925-934
Homma et al., Ann Clin Transl Neurol 2015, 2:151-166
Jones and Jones, PLoS One 2018, 13:e0192657
Jones et al., Hum Mol Genet 2012, 21:4419-4430
Jones et al., PLoS One 2016, 11:e0150938
Kowaljow et al., Neuromuscul Disord 2007, 17:611-623
Lemmers et al., Am J Hum Genet 2007, 81:884-894
Lemmers et al., Nat Genet 2012, 44:1370-1374
Lemmers et al., Science 2010, 329:1650-1653
Mitsuhashi et al., Biol Open 2018, 7:bio033977
Mitsuhashi et al., Hum Mol Genet 2013, 22:568-577
Mostacciuolo et al., Clin Genet 2009, 75:550-555; Norwood et al, Brain 2009, 132:3175-3186
Norwood et al, Brain 2009, 132:3175-3186
Padberg et al., Muscle Nerve 1995, 2:S73-S80
Padberg et al., Muscle Nerve 1995, 2:S81-S84; Flanigan et al., Neuromuscul Disord 2001, 11:525-529
Shadle et al., PLoS Genet 2017, 13:e1006658
Snider et al., PLoS Genet 2010, 6:e1001181
Tawil R. and Van Der Maarel S.M. Muscle Nerve 2006, 34:1-15
van Overveld et al., Nat Genet 2003, 35:315-317
Wallace et al., Ann Neurol 2011, 69:540-552
Wijmenga et al., Nat Genet 1992, 2:26-30
Wuebbles et al. Int J Clin Exp Pathol 2010, 3:386-400

Also Published As

Publication number Publication date
CN114026234A (zh) 2022-02-08
JP7627495B2 (ja) 2025-02-06
JPWO2021010301A1 (https=) 2021-01-21
BR112021024764A2 (pt) 2022-04-19
WO2021010301A1 (ja) 2021-01-21
IL288596A (en) 2022-02-01
AU2020313255A1 (en) 2022-01-06
US20220364086A1 (en) 2022-11-17
EP3998108A4 (en) 2024-10-30
TW202117015A (zh) 2021-05-01
EP3998108A1 (en) 2022-05-18
CA3142925A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
EP2135948B1 (en) ENA nucleic acid drugs modifying splicing in mRNA precursor
EP3472362B1 (en) Papd5 and papd7 inhibitors for treating an hepatitis b infection
WO2020043750A9 (en) Neoantigen engineering using splice modulating compounds
KR20220032004A (ko) DUX4 프리-mRNA의 스플라이싱을 변화시키는 안티센스 올리고뉴클레오티드
EP3816286A1 (en) Myocardial dysfunction therapeutic agent
JP6934695B2 (ja) 核酸医薬とその使用
HK40065915A (en) Antisense oligonucleotide capable of altering splicing of dux4 pre-mrna
JPWO2019009299A1 (ja) α−シヌクレイン発現抑制するＥＮＡアンチセンスオリゴヌクレオチド
US11230709B2 (en) Therapeutic drug for Alport's syndrome
HK40040396A (en) Myocardial dysfunction therapeutic agent
EP3146970B1 (en) Nucleic acid drug for inducing skipping of variant exon of cd44 gene and increasing expression of normal type cd44 mrna
HK40015131A (en) Therapeutic drug for alport's syndrome
HK40004694A (en) Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203